A Phase II and Pharmacokinetic Study of Weekly 72-h Topotecan Infusion in Patients with Platinum-Resistant and Paclitaxel-Resistant Ovarian Carcinoma

By Rose P.G.   Gordon N.H.   Fusco N.   Fluellen L.   Rodriguez M.   Ingalls S.T.   Hoppel C.L.  

Gynecologic Oncology, Vol. 78, Iss. 2, 2000-08 ,pp. : 228-234

Elsevier

Access to resources Recommend Favorite

Activity of docetaxel in paclitaxel-resistant ovarian cancer cells

By Sato Shinya   Kigawa Junzo   Kanamori Yasunobu   Itamochi Hiroaki   Oishi Tetsuro   Shimada Muneaki   Iba Takahiro   Naniwa Jun   Uegaki Kazunori   Terakawa Naoki  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 3, 2004-03 ,pp. : 247-252

Springer Publishing Company

Access to resources Recommend Favorite

Phase 2 Evaluation of Topotecan Administered on a 3-Day Schedule in the Treatment of Platinum- and Paclitaxel-Refractory Ovarian Cancer

By Markman M.   Kennedy A.   Webster K.   Kulp B.   Peterson G.   Belinson J.  

Gynecologic Oncology, Vol. 79, Iss. 1, 2000-10 ,pp. : 116-119

Elsevier

Access to resources Recommend Favorite

Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy for Platinum-Refractory and -Resistant Ovarian Cancer

By Bolis G.   Parazzini F.   Scarfone G.   Villa A.   Amoroso M.   Rabaiotti E.   Polatti A.   Reina S.   Pirletti E.  

Gynecologic Oncology, Vol. 72, Iss. 1, 1999-01 ,pp. : 60-64

Elsevier

Access to resources Recommend Favorite

In vivo establishment and characterization of a paclitaxel-resistant human ovarian cancer cell line showing enhanced growth properties and drug-resistance only in vivo

By Okugawa Kaoru   Kobayashi Hiroaki   Hirakawa Toshio   Sonoda Takanori   Ogura Tomonori   Nakano Hitoo  

Journal of Cancer Research and Clinical Oncology, Vol. 130, Iss. 3, 2004-03 ,pp. : 178-186

Springer Publishing Company

Access to resources Recommend Favorite